US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis Inc. (NASDAQ:PSNL) received a favorable reimbursement decision that could make its cancer test available to more patients — and more likely to be paid for by Medicare.
PSNL - Personalis, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.00
DETAILS
HIGH:
$13.00
LOW:
$9.00
MEDIAN:
$11.00
CONSENSUS:
$11.00
UPSIDE:
29.87%
Stock News
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Canc.
Personalis to Participate in Upcoming Investor Events
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026 at the Depot Renaissance Hotel in Minneapolis, MN. Jefferies 2026 Global Healthcare Conference on June 3, 2026 at the Marriot Marquis in New York, NY. About Personalis, Inc. At Personalis, we are transformi.
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare and Medicaid Services' (CMS)
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in.
Personalis Q1 Earnings Call Highlights
Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.
Personalis Reports First Quarter Results and Recent Highlights
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent business accomplishments, and reaffirmed financial guidance for the full year 2026. First Quarter and Recent Strategic and Operational Highlights Secured Milestone Medicare Coverage for Lung Cancer: Received Medicare coverage approval in the first quarter for the su.
Personalis to Announce First Quarter 2026 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domesti.
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California. A focus of this year's data is the introduction of a new NeXT Personal MRD test option.
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc
Aberdeen Group plc lifted its holdings in shares of Personalis, Inc. (NASDAQ: PSNL) by 36.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,249,895 shares of the company's stock after acquiring an additional 861,948 shares during the
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to
Personalis to Participate in the 25th Annual Needham Virtual Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our hig.
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific.
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease," showed that ultrasensitive molecular residual disease (MRD) testing with NeXT Personal can perform.
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Analysts
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to
Personalis, Inc. (NASDAQ:PSNL) Sees Large Increase in Short Interest
Personalis, Inc. (NASDAQ: PSNL - Get Free Report) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 10,685,978 shares, an increase of 21.2% from the January 29th total of 8,813,216 shares. Currently, 12.5% of the company's stock are short sold. Based on an average
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Price Targets
Personalis price target lowered to $9 from $10 at Morgan Stanley
$9.00
(was $5.93)
Morgan Stanley
Personalis price target lowered to $11 from $13 at BTIG
$11.00
(was $5.98)
Mark Massaro
·
BTIG
Personalis price target raised to $13 from $12 at Guggenheim
$13.00
(was $10.53)
Subbu Nambi
·
Guggenheim
Personalis assumed with an Equal Weight at Morgan Stanley
$11.00
(was $9.68)
Kallum Titchmarsh
·
Morgan Stanley
Personalis price target raised to $11 from $9 at Lake Street
$11.00
(was $8.25)
Thomas Flaten
·
Lake Street
Personalis (PSNL) PT Raised to $10 at Needham
$10.00
(was $8.73)
Mike Matson
·
Needham
Personalis price target lowered to $6 from $8 at BTIG
$6.00
(was $4.41)
Mark Massaro
·
BTIG
Personalis price target raised to $8 from $4 at Lake Street
$8.00
(was $5.91)
Thomas Flaten
·
Lake Street
Personalis price target raised to $9 from $7.50 at H.C. Wainwright
$9.00
(was $5.99)
Swayampakula Ramakanth
·
H.C. Wainwright
Personalis (PSNL) PT Raised to $7 at BTIG
$7.00
(was $5.99)
Mark Massaro
·
BTIG
Personalis (PSNL) PT Raised to $5.50 at BTIG
$5.50
(was $3.43)
Mark Massaro
·
BTIG
Personalis (PSNL) PT Raised to $5.50 at Needham
$5.50
(was $2.88)
Mike Matson
·
Needham
Needham Reiterates Buy Rating on Personalis (PSNL)
$3.50
(was $1.22)
Mike Matson
·
Needham
Lake Street Capital Markets Starts Personalis (PSNL) at Buy
$4.00
(was $1.47)
Thomas Flaten
·
Loop Capital Markets
Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $13
$13.00
(was $5.16)
Morgan Stanley